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Molecular Pathology:
Unlocking the Cell's
Secrets
Editor's note: This "Under the
Scope" is the first in a series of
profiles on areas of intramural
research atthe NIEHS.
The secrets to the origins of cancer
are hidden deep within cells. Re-
searchers in the Laboratory of Experimental
Pathology (LEP) at the NIEHS are using the
techniques of molecular biology to uncover
the role ofenvironmental agents in changing
the molecular structure ofcells that may lead
to cancer.
Traditional pathology consisted of using
stained tissue sections for diagnosis and for
identifying specific tissue alterations such as
identification of infectious organisms and
demonstration ofspecific cellular enzymes. A
second generation ofspecialized stains based
on immunohistochemistry provided infor-
mation about the presence and localization
ofspecific proteins for which polyclonal and
monoclonal antibodies were available.
Today, molecular pathology laboratories are
using molecular methods such as in situ
hybridization staining to detect specific mes-
senger RNAs. These methods allow a
researcher to show whether a cell has actually
produced a protein, rather than just stored it.
Because changes in gene expression (indicat-
ed by changes in mRNA) are associated with
induction and progression of tumors, in situ
hybridization offers scientists a means ofteas-
ing out the underpinnings of the cancer
process. Other dimensions of molecular
pathology including extraction of
cellular DNA and RNA as well as
proteins from tumors and iden-
tification of this material using
electrophoresis and other mole-
cular biology techniques have
led to identification of several
oncogenes in human and animal
cancers.
Oncogene Clues
Lung cancer is one ofthe most common can-
cers in the United States. Worldwide, liver
cancers are the most common. Most animal
carcinogenicity studies have been conducted
in mouse lung or liver cells because mice
readily develop tumors in these sites when
exposed to carcinogenic agents. Efforts led by
Robert Maronpot, chief of the LEP, are
ongoing in the laboratory to better under-
stand these tumor endpoints and their utility
in hazard identification and human risk
assessments. "We hope that there are bridges
between tissues and across species that will
enable us to transfer this information to
humans," Maronpot said. "If something is
occurring molecularly, then we might find a
way to block it, thus blocking cancer, or pro-
vide methods for better therapies."
Early molecular pathology studies con-
ducted by the LEP in collaboration with
other NIEHS researchers looked at DNA
from tumor cells and adjacent tissues in mice
for alterations to proto-oncogenes, normal
genes that mutate slightly to become onco-
genes and cause cancer. After identifying a
gene, the investigators treated the animals
with an environmental agent to determine if
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the gene's activity changed, such as causing
more tumors to develop than in normal mice
or causing tumors to develop sooner. For
example, researchers found that tetra-
chloroethylene and trichloroethylene, widely
used industrial solvents and common conta-
minants of surface, ground, and drinking
water, and dichloroacetic acid, a metabolite
of trichloroethylene and a major organic
contaminant of chlorinated drinking water,
activated oncogenes in induced liver tumors.
This activation led to an early increase in
liver tumor incidence in one strain of mice.
Some of the activated oncogenes in these
tumors differed from those found in tumors
that occurred spontaneously.
Past studies have shown that oncogene
activation is more frequent in tumors
induced by low doses of hepatocarcinogens
than by high doses and provides evidence
that the mechanisms or pathways of tumor
induction differ as a function of the dose of
carcinogen. Dave Malarkey is currently
studying the dose-response relationship to
oncogene activation. The implications of
identifying a dose-dependent effect on the
mechanism oftumor induction directly chal-
lenge the risk assessment assumption that
chemical carcinogens at low and high doses
produce cancer by the same mechanisms.
Most of the oncogene studies in mouse
liver tumors have been done at NIEHS, says
Maronpot. However, the focus is shifting
away from these studies because not all
induced or spontaneous liver tumors have
been shown to carry an activated oncogene,
making it difficult to draw definitive conclu-
sions. Some of these types of studies will
continue though, in the hopes ofdiscovering
new oncogenes. "We determined that some
agents that cause cancer in animals, and pre-
sumably in man, do so by activating onco-
genes, which may tell us something about
risk assessment. Also, some of the specific
mutations in activated oncogenes identified
in animal tumors match what is seen in
human tumors, which offers the hope that
the basic fundamental molecular mecha-
nisms maybe similar," said Maronpot.
In addition, retrospective studies are
being designed to identify specific genetic
alterations in neoplasms from some of the
450 previous two-year chemical bioassays.
These studies will attempt to correlate chem-
ical-specific properties including structural
features, genotoxicity, and metabolism with
characteristics of genetic alterations in pre-
neoplastic and neoplastic lesions of specific
target organs. These studies will allow scien-
tists to compare classes ofchemicals, evaluate
structure-activity relationships within classes,
and determine the response of target tissues
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long-term studies. Chemicals for which
genetic alterations (oncogene activation)
have been determined include oxazepam,
vinyl carbamate, chlordane, trichloroethyl-
ene, tetrachloroethylene, dichloracetic acid,
furan, and butadiene.
The Transgenic Track
A new focus is on transgenic mice. The mice
are genetically engineered to carry human or
mouse oncogenes or genes for certain growth
factors. "They offer a unique approach to
identifying and investigating factors that may
influence tumor development by allowing us
to directly assess what these genes do in tar-
get organs and how they are influenced by
environmental agents," Maronpot says.
Some transgenic mice develop tumors in as
little as 6 months when exposed to certain
chemicals, as opposed to the normal 18- to
24-month time span. The mice hyperre-
spond to test agents, enabling the investiga-
tors to obtain answers to their questions
much faster than with traditional models.
LEP investigators will soon begin study-
ing a strain of transgenic mice developed in
Japan that carries a normal human H-ras
proto-oncogene. When these mice were
exposed to potent carcinogens, this gene was
activated in the induced tumors. Maronpot
and his colleagues will expose the mice to
environmental chemicals to which people
may be exposed such as chloroform, chlor-
dane, ethyl acrylate, and furan, which have
previously been shown to cause cancer in
laboratory animals. If the mice respond as
expected, they will be used to test agents
whose effects are unknown. "The questions
are, however, Are we going to miss some-
thing with this technique or will we be over-
predicting which agents cause cancer?"
Maronpot says. "So far, these mice show a
lot ofpromise. Ifwe show that environmen-
tal agents produce tumors containing an
activated human H-ras gene, then we could
warn people about their exposure."
Sleuthing in situ
A relatively new area ofinvestigation involves
in situ hybridization, which allows re-
searchers to identify proteins produced by
specific genes in the tissue where these pro-
teins are normally found.
Most of the current LEPin situ studies
involve mouse ovarian toxicity and cancer.
Barbara Davis, a guest researcher in the LEP,
and researcher Kathy Phillips are studying
estradiol, a hormone neccesary for reproduc-
tion, in ovarian granulosa cells, which line
the egg-containing follicles, to determine the
effect of environmental agents on estradiol
production. Because estradiol production is
the same in animals and humans, it may be a
good system for comparing toxicity.
Specifically, Davis is investigating how
environmental agents
act on aromatase, an
enzyme that converts
testosterone to estra-
diol and also acts on
the estrogen and
androgen receptors.
The studies are per-
formed in whole tis-
sue and then in situ
in specific rat ovarian
cells. The primary
agents under invest-
igation are di(2-eth-
ylhexyl)phthalate,
which rat studies
have shown suppress-
es estradiol produc-
tion, and other
phthalates to see if
Ovarian variation. Using in situ hybridization, researchers can study expres-
sion ofthe oncogeneWT1 in ovarian cells.
this class of agents
has the same actions. "Phthalates are ubiqui-
tous in the environment," Davis says.
Phthalates are components of plastics and
readilyleech into the environment.
LEP and other NIEHS researchers will
also study mercury vapor using in vivo rat
studies and in vitro rat and human granulosa
cells. "We will look at these cells in vitro,"
Davis said. "If we determine that mercury
disrupts the pathways, then it implies that
these pathways are likely to be disrupted in
humans also." A 1994 study by NIEHS epi-
demiologist Andrew Roland found that
female dental assistants with high occupa-
tional exposure to mercury (by making mer-
cury amalgam tooth fillings) were less fertile
than unexposed dental assistants.
Davis is using in situhybridization stud-
ies to generate markers to identify the genes
affected in ovarian cancer. There are not
many studies on agents that cause ovarian
cancer, although ovarian cancer is the fifth
leading cause ofcancer death in women. "If
we better understood the underlying mech-
anism that causes ovarian cancer, we could
develop preventative measures," Davis said.
Davis and Phillips are studying theWTI
marker, an oncogene expressed in immature
and adult ovarian cells, using an in situ
method developed by pathologist Akiko
Enomoto. They are also investigating the
tumor-suppressor gene p53, and BRCA1,
an oncogene involved in inherited breast
tumors as well as in ovarian cancer. These
studies are being conducted using molecu-
lar probes, synthetic complementary copies
ofDNA sequences used to look for messen-
ger protein expression.
These studies use in situ polymerase
chain reaction (PCR), which allows the
researchers to make millions ofcopies ofany
DNAsequence.
Signs ofPromise
Other ongoing research areas in the LEP
include the development of immunohisto-
chemistry methods for cell products such as
p53, estrogen receptors, fibroblast growth
factors (FGF-f), and other products related
to cell growth and proliferation. The repro-
ductive pathobiology group of the LEP, led
by Darlene Dixon, is using immunohisto-
chemical staining of mouse and human tis-
sues to assess the presence of several growth
factors in uterine tumors. Preliminary find-
ings show that one particular growth factor,
TGF-a is found in uterine smooth muscle
tumors and expression increases with malig-
nancy. Immunolocalization ofa mature form
of this growth factor has been found exclu-
sively in malignant uterine smooth muscle
tumors in mice.
Other techniques are under development
such as in situ polymerase chain reaction
(PCR) which will allow the amplification of
specific sequences ofDNA and RNA present
in small amounts in individual cancerous
cells. The technique enables researchers to
amplify or make copies ofa gene inside a cell,
without destroying it, attach a color marker,
and identify where a "bad" gene is located.
"We want to understand how genes are acti-
vated, and when that occurs in the process in
intact tissue, not tissue extract." Maronpot
says. "This technique will allow us to identify
damaged cells. Although many cells are
exposed to the environmental agent, only
some change, others die or are repaired. But
the cell that did notdie or repairitself, perpet-
uates the damage." Maronpot stresses that the
contributions ofmolecular pathology must be
combined with those of scientists in many
disciplines including chemistry, toxicology,
and physiology to unlock the secrets of how
environmental agents affecthuman cells.
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Volume 103, Number 6, June 1995 549